ByteDance Divides Its AI Pharmaceuticals Team: Why Would a Giant Company “Slow Down” Behind $290 Million in Financing?
Hello everyone, I’m your financial observer. Today, we’re discussing a news story that may seem like a “cross-industry move” but actually carries significant implications: ByteDance has separated its internal AI pharmaceuticals team to establish a new company called Anew Labs, which has raised a stunning $290 million (approximately RMB 2 billion) in its initial round of financing, with a valuation of $1.5 billion.
Many people might wonder, “Isn’t ByteDance mainly involved in developing apps like TikTok and games? Why would they suddenly get into pharmaceuticals?” Moreover, pharmaceuticals are known to be a “slow business,” so why would a tech giant like ByteDance, known for its fast iteration, tackle such a challenging field?
Let’s break down the details to understand the context better. This isn’t just a single move by ByteDance; it’s also an important vote by the entire tech industry on the future direction of “AI + biomedicine.”
---
Summary of Key Points:
- What happened?
- ByteDance has created a new company, Anew Labs, by separating its “AI for Science” drug discovery team.
- Anew Labs has completed a $290 million financing round, with a post-funding valuation of $1.5 billion.
- ByteDance still holds a 56% stake, maintaining absolute control.
- Investors include top firms like Sequoia China (HSG), IDG, Hillhouse Capital, and Wuyuan Capital, as well as industry players like China BioPharmaceutical.
- Anew Labs’ mission is to become a “end-to-end” AI-based drug discovery company, focusing on developing small molecule drugs that target specific inflammatory factors.
In-depth Analysis:
1. **Rhythm Conflict: The Incompatibility between Fast Internet and Slow Pharmaceuticals**
- The internet operates on a “quick iteration” model: launching features, analyzing data, and making improvements daily or even hourly. If it doesn’t work, it’s removed immediately. The cycle is measured in weeks or days.
- Pharmaceuticals, on the other hand, follow the “10 years, 1 billion dollars” rule: from discovering a molecule to a drug’s market launch, there are countless experiments and clinical trials, with a validation cycle measured in years.
- Keeping the pharmaceutical team within ByteDance would create a mismatch in KPIs, leading to motivational issues and potential talent turnover.
- Independence gives Anew Labs its own timeline and evaluation system, allowing it to grow at the pace of the pharmaceutical industry.
2. **Talent and Capital: Independent Status for Better Recruitment and Financing**
- Top pharmaceutical scientists and biologists prefer to work in specialized companies or research institutions. Anew Labs, as a standalone entity, can attract these professionals more effectively.
- Pharmaceutical research is costly, so independent companies can attract long-term investors like China BioPharmaceutical and other capital providers.
- By separating the team, ByteDance can focus on building its own drug development pipeline, rather than just providing tools.
3. **Strategic Positioning: Moving from a Tool Provider to a Player**
- Many tech companies in AI pharmaceuticals merely sell software and computing power. Anew Labs aims to develop drugs from start to finish, taking on all the risks and potential rewards.
- Its core product is a small molecule inhibitor that targets three types of IL-17 family dimers, which has significant market potential for autoimmune diseases.
- This indicates that ByteDance believes AI is mature enough to lead drug discovery, not just support it.
4. **Industry Trends: The Two Paths of AI in Pharmaceuticals**
- There are two main approaches: either developing drugs in-house or providing platforms for others to use. ByteDance has chosen the former, showing its confidence in AI’s role in drug discovery.
5. **Long-Term Vision: AI in Pharmaceuticals as a Must-Have**
- Traditional drug development methods are inefficient and costly. AI can significantly speed up the process and reduce costs.
- ByteDance has been preparing for this for years, starting with talent recruitment in 2020 and team formation in 2021, leading to the separation in 2026.
Implications for You:
- Investment Perspective: Pay attention to AI + biomedicine as a long-term trend. Companies with both AI technology and in-house pipelines offer high potential returns.
- Career Perspective: There’s a growing demand for “AI + biology” professionals. This is a great time to enter this field.
- Health Perspective: AI in pharmaceuticals could lead to cheaper and more effective drugs, especially for diseases with limited treatments.
Conclusion:
ByteDance’s separation of Anew Labs is more than a business adjustment; it’s a strategic shift towards becoming a player in the AI pharmaceuticals industry. This move reflects the industry’s shift towards using AI as a core tool for drug discovery. The success of Anew Labs will have a significant impact on the pharmaceutical landscape.
The $290 million in financing is just the beginning. What really matters is how quickly AI can reduce the long development cycles and shape the future of pharmaceuticals.